US · Basic Materials · Specialty Chemicals
EPS came in at 1.49 against a street estimate of 1.40 — a beat of 6.4%.
Analysts rate Balchem Corporation a buy (2 buy, 0 hold, 0 sell out of 2) with an average price target of $209.25.
CONFIDENT Balchem delivered record Q2 revenue ($284M, +11.2% YoY) and adjusted EPS ($1.49), beating street estimates. All three segments grew; Human Nutrition led with +10% sales. 28 consecutive quarters of EBITDA growth achieved. Q2 2026 Europe monogastric recovering following EU antidumping duties implemented Jan 2026; noted as improving every quarter with volume share gains and price recovery. Analysts pressed on nutrient product strategy (build vs. buy rationale), clinical trial timelines (Alzheimer's study), and ANH segment acceleration (volume vs. pricing split). Management credited science-first approach, targeted influencer/GLP-1 marketing, and EU antidumping recovery as growth drivers. 2026-07-31…
Full summary in the app.
| Fund | Stake |
|---|---|
| BlackRock Inc | 15.19% |
| Vanguard Portfolio Management, LLC | 6.88% |
| Vanguard Capital Management, LLC | 4.49% |
| State Street Corp | 3.89% |
| Conestoga Capital Advisors, LLC | 3.41% |
| Wasatch Advisors LP | 3.30% |
| Geode Capital Management, LLC | 3.29% |
| Morgan Stanley - Brokerage Accounts | 2.69% |
| Document | Date |
|---|---|
| Quarterly report · Q2 2026 BALCHEM CORPORATION – Q2 2026 10-Q SUMMARY HEADLINE NUMBERS • Net Sales (6M 2026): $554.7 million vs $506.0 million (2025) — up 9.6% • Net Earnings | 2026-07-31 |
| Results announced · Q3 2026 BALCHEM CORPORATION Q2 2026 FINANCIAL SUMMARY HEADLINE NUMBERS • Net sales: $284.0 million, up 11.2% year-over-year • Net earnings: $44.6 million, u | 2026-07-31 |
| Material agreement · Q3 2026 BALCHEM CORPORATION (BCPC) – FORM 8-K SUMMARY As of July 24, 2026 --- HEADLINE NUMBERS • Revolving credit facility increased from $550 million to $ | 2026-07-27 |
| Shareholder vote results · Q2 2026 BALCHEM CORPORATION - FORM 8-K SUMMARY HEADLINE NUMBERS • Annual Meeting of Shareholders held June 18, 2026 • Company trades under ticker BCPC on Na | 2026-06-22 |
| Quarterly report · Q1 2026 BALCHEM CORPORATION – Q1 2026 10-Q SUMMARY --- HEADLINE NUMBERS • Net Sales: $270.7M (Q1 2026) vs. $250.5M (Q1 2025) — 8.0% increase • Net Earnings | 2026-04-30 |
| Results announced · Q2 2026 BALCHEM CORPORATION Q1 2026 EARNINGS SUMMARY HEADLINE NUMBERS • Net sales: $270.7 million, up 8.1% from $250.5 million in Q1 2025 • Net earnings: $4 | 2026-04-30 |
| Proxy statement · Q2 2026 BALCHEM CORPORATION PROXY STATEMENT SUMMARY FOR RETAIL INVESTORS CEO TOTAL COMPENSATION & CHANGE • CEO total compensation for 2025: $4,356,747 (exact | 2026-04-27 |
| Annual report FY2025 BALCHEM CORPORATION FORM 10-K SUMMARY Fiscal Year Ended December 31, 2025 --- HEADLINE NUMBERS • Market capitalization (as of June 30, 2025): $5,13 | 2026-02-20 |
Readable in the app.
| Action | Detail | Date |
|---|---|---|
| Dividend | $0.96 / share ex-date Dec 23, 2025 · pay Jan 20, 2026 | 2025-12-23 |
| Announcement | Date |
|---|---|
| Board approves new stock repurchase program for up to 4 million shares Balchem Corporation announced two shareholder-friendly actions on December 9-10, 2025: (1) a dividend declaration by the Board of Directors, and (2) approval of a new stock repurchase progra | 2025-12-10 |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Balchem Corporation — free to start.
Google PlayApp StoreData updated 2026-09-18.